395 related articles for article (PubMed ID: 37272513)
1. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H; Liberman M; Kato T; Tsuboi M; Lee SH; Gao S; Chen KN; Dooms C; Majem M; Eigendorff E; Martinengo GL; Bylicki O; Rodríguez-Abreu D; Chaft JE; Novello S; Yang J; Keller SM; Samkari A; Spicer JD;
N Engl J Med; 2023 Aug; 389(6):491-503. PubMed ID: 37272513
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
3. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
5. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
7. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S; Zhang W; Wu L; Wang W; Zhang P; ; Fang W; Xing W; Chen Q; Yang L; Mei J; Tan L; Sun X; Xu S; Hu X; Yu G; Yu D; Yang N; Chen Y; Shan J; Xing L; Tian H; Zhang X; Zhou M; Fang H; Wu G; Liu Y; Ye M; Cao L; Jiang J; Li X; Zhu L; Li D; Kang M; Zhong A; Chen K; Wu N; Sun Q; Ma H; Cai K; Wang C; Lin G; Zhu K; Zhang Y; Zhang X; Hu H; Zhang W; Chen J; Yang Z; Hang X; Hu J; Huang Y; Zhang Z; Zhang L; Zhang L; Liu L; Lin D; Zhang J; Chen G; Li Y; Zhu L; Wang W; Yu W; Cao D; Keegan P; Yao S
JAMA; 2024 Jan; 331(3):201-211. PubMed ID: 38227033
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Nivolumab in Resectable Lung Cancer.
Cascone T; Awad MM; Spicer JD; He J; Lu S; Sepesi B; Tanaka F; Taube JM; Cornelissen R; Havel L; Karaseva N; Kuzdzal J; Petruzelka LB; Wu L; Pujol JL; Ito H; Ciuleanu TE; de Oliveira Muniz Koch L; Janssens A; Alexandru A; Bohnet S; Moiseyenko FV; Gao Y; Watanabe Y; Coronado Erdmann C; Sathyanarayana P; Meadows-Shropshire S; Blum SI; Provencio Pulla M;
N Engl J Med; 2024 May; 390(19):1756-1769. PubMed ID: 38749033
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L; Luft A; Vicente D; Tafreshi A; Gümüş M; Mazières J; Hermes B; Çay Şenler F; Csőszi T; Fülöp A; Rodríguez-Cid J; Wilson J; Sugawara S; Kato T; Lee KH; Cheng Y; Novello S; Halmos B; Li X; Lubiniecki GM; Piperdi B; Kowalski DM;
N Engl J Med; 2018 Nov; 379(21):2040-2051. PubMed ID: 30280635
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
[TBL] [Abstract][Full Text] [Related]
13. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Chang YH; Lee JL; Sarwar N; Haas NB; Gurney H; Sawrycki P; Mahave M; Gross-Goupil M; Zhang T; Burke JM; Doshi G; Melichar B; Kopyltsov E; Alva A; Oudard S; Topart D; Hammers H; Kitamura H; McDermott DF; Silva A; Winquist E; Cornell J; Elfiky A; Burgents JE; Perini RF; Powles T;
N Engl J Med; 2024 Apr; 390(15):1359-1371. PubMed ID: 38631003
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV; Luke JJ; Khattak MA; de la Cruz Merino L; Del Vecchio M; Rutkowski P; Spagnolo F; Mackiewicz J; Chiarion-Sileni V; Kirkwood JM; Robert C; Grob JJ; de Galitiis F; Schadendorf D; Carlino MS; Mohr P; Dummer R; Gershenwald JE; Yoon CH; Wu XL; Fukunaga-Kalabis M; Krepler C; Eggermont AMM; Ascierto PA;
Lancet Oncol; 2022 Nov; 23(11):1378-1388. PubMed ID: 36265502
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ; Rutkowski P; Queirolo P; Del Vecchio M; Mackiewicz J; Chiarion-Sileni V; de la Cruz Merino L; Khattak MA; Schadendorf D; Long GV; Ascierto PA; Mandala M; De Galitiis F; Haydon A; Dummer R; Grob JJ; Robert C; Carlino MS; Mohr P; Poklepovic A; Sondak VK; Scolyer RA; Kirkwood JM; Chen K; Diede SJ; Ahsan S; Ibrahim N; Eggermont AMM;
Lancet; 2022 Apr; 399(10336):1718-1729. PubMed ID: 35367007
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
19. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
